Abstract:Background: Annonaceous acetogenins (ACGs) are secondary metabolites produced by the Annonaceae family and display potent anticancer activity against various cancer cell lines. Squamocin and bullatacin are two examples of ACGs that show promising antitumor activity; however, preclinical data are not sufficient partly due to their being highly lipophilic and poorly soluble in water. These compounds also display high toxicity to normal cells. Due to these disadvantageous properties, the therapeutic potential of squamocin and bullatacin as antitumor agents has not been fully evaluated. Methods: In order to enhance their water solubility and potentially improve their cancer targeting, squamocin and bullatacin were conjugated to a glucose or galactose to yield glycosylated derivatives by direct glycosylation or the Cu(I)-catalyzed azide-alkyne 1,3-dipolar cycloaddition (CuAAC) reaction (the click reaction). The synthesized compounds were evaluated for their anticancer property against HeLa, A549 and HepG2 cancer cell lines using MTT assay. Results: Nine glycosyl derivatives were synthesized and structurally characterized. Most of them show comparable in vitro cytotoxicity against HeLa, A549 and HepG2 cancer cell lines as their parent compounds squamocin and bullatacin. It appears that the type of sugar residue (glucose or galactose), the position at which the sugar residue is attached, and whether or not a linking spacer is present do not affect the potency of these derivatives much. The solubility of galactosylated squamocin 13 in phosphate buffer saline (PBS, pH = 7) is greatly improved (1.37 mg/mL) in comparison to squamocin (not detected in PBS). Conclusion: The conjugation of a glucose or galactose to squamocin and bullatacin yields glycosyl derivatives with similar level of anticancer activity in tested cell lines. Further studies are needed to demonstrate whether or not these compounds show reduced toxicity to normal cells and their therapeutic potential as antitumor agents.

Synthesis and in Vitro Anti-tumor Evaluation of Novel Glycoconjugated SN38 Derivatives

Discovery of highly potent and selective 7-ethyl-10-hydroxycamptothecin-glucose conjugates as potential anti-colorectal cancer agents

Synthesis and Biological Evaluation of Novel SN38-glucose Conjugate for Colorectal Cancer Treatment

Design, Synthesis, and Evaluation of Glucose Transporter Inhibitor-SN38 Conjugates for Targeting Colorectal Cancer

"Sweet Tooth"-Oriented SN38 Prodrug Delivery Nanoplatform for Targeted Gastric Cancer Therapy.

Design, Synthesis of Novel Platinum(II) Glycoconjugates, and Evaluation of Their Antitumor Effects.

Synthesis and Biological Evaluation of Novel Spin Labeled 18Β-Glycyrrhetinic Acid Derivatives

Synthesis and Antitumor Evaluation of Biotin-SN38-Valproic Acid Conjugates

5-Fluorocytosine–Sugar Conjugates for Glucose Transporter-Mediated Tumor Targeting: Synthesis, Cytotoxicity, and Cellular Uptake Mechanism

Synthesis and Cytotoxic Property of Annonaceous Acetogenin Glycoconjugates

Synthesis and Biological Evaluation of Novel Conjugates of Camptothecin and 5-Flurouracil As Cytotoxic Agents

Synthesis, Characterization, and Antitumor Evaluation of the Albumin–sn38 Conjugate

Synthesis and Anti-Tumor Evaluation of Novel C-37 Modified Derivatives of Gambogic Acid

The Synthesis of Several Glycoconjugates of Camptothecin and the Study of Their Anti-Tumor Activities

Synthesis of Tigogenin MeON-Neoglycosides and Their Antitumor Activity

Design, Synthesis and Anti-Tumor Evaluation of Novel Steroidal Glycoconjugate with Furoxan Derivatives.

The Synthesis of Several Glycoconjugates of Camptothecin

Synthesis and Biological Evaluation of Novel 10-Substituted-7-ethyl-10-hydroxycamptothecin (SN-38) Prodrugs

Synthesis and In vitro anti-cancer Activity evaluation of Glucosamine Derivatives

Synthesis and biological evaluation of novel 5,6,7-trimethoxy flavonoid salicylate derivatives as potential anti-tumor agents

Novel SN38 Conjugate-Forming Nanoparticles As Anticancer Prodrug: in Vitro and in Vivo Studies.